Articles Published in 2013

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

Baxter, Coherus Biosciences collaborate

Wednesday, September 4, 2013 12:09 PM

Baxter International and Coherus Biosciences, a San Francisco Bay area-based clinical stage, pure-play biosimilar company, have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada and Brazil. Biosimilars are intended to be used in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases and have the potential to reduce costs and expand patient access.

More... »

Dropout rates for phase I oncology trials remain under 10%

Wednesday, September 4, 2013 12:04 PM

The overall dropout rate for oncology phase I trials is only 8%, according to a study by Cutting Edge Information. However, dropout rates tend to rise as the number of required visits increases.

More... »

ClinEdge, ClinicalConnection partner

Wednesday, September 4, 2013 12:03 PM

ClinEdge, a Boston-based full-service marketing, patient recruitment and clinical operations firm, has partnered with database company ClinicalConnection and ClinicalConnection.com, a web site for clinical trial searches, notifications and patient referrals. More than 250,000 people visit ClinicalConnection.com each month.

More... »

NIHR launches online neurodegenerative disease research showcase

Wednesday, September 4, 2013 12:01 PM

To mark the start of World Alzheimer’s Month, the National Institute for Health Research (NIHR) is showcasing clinical research that could bring new hope to dementia patients and their families, and those with other neurodegenerative diseases, with the launch of www.FocusOnDementia.nihr.ac.uk. 

More... »

Neurotrope completes reverse merger

Wednesday, September 4, 2013 11:58 AM

Nevada-based Neurotrope (formerly BlueFlash Communications) has completed a reverse merger in which Neurotrope BioScience, based in Delaware, became a wholly owned subsidiary of the company.

More... »

Wellcome Trust, KU Leuven, Janssen collaborate

Wednesday, September 4, 2013 11:53 AM

Wellcome Trust, Janssen and KU Leuven are collaborating for dengue antiviral drugs. The collaboration will build on an existing three-year drug discovery program at the Rega Institute and the Center for Drug Design and Discovery (CD3) at KU Leuven, supported by a Wellcome Trust Seeding Drug Discovery Award.

More... »

The CenterWatch Monthly, September 2013

Tuesday, September 3, 2013 08:00 AM

Sponsors look to collaborate on comparator drugs

More... »

Mount Sinai, Exosome Diagnostics partner

Friday, August 30, 2013 02:29 PM

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics are collaborating on the R&D of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The five-year agreement will allow the companies to establish targeted research and biomarker discovery programs in oncology and inflammation. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

More... »

Endo to acquire Boca Pharmacal

Friday, August 30, 2013 02:29 PM

Endo Health Solutions, a U.S.-based specialty healthcare company, will acquire privately-held Boca Pharmacal, a specialty generics company, for $225 million in cash. Boca Pharmacal focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.

More... »